If these drugs are reducing dopamine signaling in the brain's reward center, what else might that affect over time
After announcing the state would initiate coverage of GLP-1s to combat obesity in September 2022 as part of their state employee health plan, the state reversed course and in January 2025 announced it was opting to end that coverage beginning July 1, 2025
In a consumer study of 274 people taking GLP-1 Probiotic for 6 weeks, 91% reported reduced food cravings
Currently, there are three FDA-approved oral GLP-1s on the market in the US: Rybelsus, which is approved for type 2 diabetes, the Wegovy pill, which is approved for weight loss, and Foundayo, which is also approved for weight loss
Each vial contains a combination of high-purity Retatrutide formulated under stringent quality control standards to ensure stability, precision, and consistency in controlled experimental research
Individuals experiencing new or worsening symptoms should seek medical care promptly and should not stop or change a prescribed medication without consulting a healthcare provider
